Effectiveness of the Oxford-AstraZeneca COVID-19 vaccine as a 2nd booster, the REFORCO-Brazil study - REFORCO-B

Study identifier:D8111R00028

ClinicalTrials.gov identifier:NCT05697705

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Real-world Effectiveness oF the OxfoRd-astrazeneca Covid-19 vaccine as a second bOoster dose in Brazil (REFORCO-BRAZIL)

Medical condition

COVID-19

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

188814085

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 22 Jul 2022
Primary Completion Date: 18 May 2023
Study Completion Date: 18 May 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria